Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aspirin therapy

This article was originally published in The Tan Sheet

Executive Summary

Daily doses of 75 mg-150 mg per day reduce risk of vascular events by 32% in high-risk patients, according to meta-analysis by Antithrombotic Trialists' Collaboration (Oxford, England) in Jan. 12 British Medical Journal. C. Baigent, et al., reviewed a total of 287 studies involving 212,000 patients that compared antiplatelet therapy with either controls or other antiplatelet regimens. Accompanying editorial by John Cleland, University of Hull, maintains aspirin efficacy is overstated since it does not reduce mortality...

You may also be interested in...

Aspirin Therapy Mortality Reduction Confirmation Urged In BMJ Editorial

A "definitively positive trial" on aspirin's effectiveness at lowering mortality due to coronary heart disease is still needed, John Cleland, University of Hull, UK, states in an editorial in the Jan. 12 British Medical Journal

Vitamin D And COVID-19 Studies: Prevention Benefits Suggested By Chicago Research

A study with nearly 500 patients with vitamin D levels tested within a year before receiving COVID-19 tests found subjects deficient in the nutrient had 1.77 greater chance of testing positive. Researchers say RCTs are needed to determine if broad population interventions are necessary.

Novocure Transforms Patient Support System During Pandemic

The company is running a pilot program to allow glioblastoma patients who use Novocure’s Optune Tumor Treating Fields device to download data from the device at home.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts